Morgan Stanley’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Morgan Stanley’s Portfolio CMTA Stock Details CMTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-24,513	Closed	-$639K	–	6917
2019 Q1	$639K	Sell	24,513 -15,972	-39%	-$298K	﹤0.01%	4409
2018 Q4	$476K	Buy	40,485 +14,912	+58%	+$186K	﹤0.01%	4816
2018 Q3	$285K	Sell	25,573 -13,857	-35%	-$146K	﹤0.01%	5292
2018 Q2	$518K	Buy	39,430 +20,316	+106%	+$329K	﹤0.01%	5076
2018 Q1	$289K	Sell	19,114 -2,531	-12%	-$41.2K	﹤0.01%	5304
2017 Q4	$411K	Sell	21,645 -45,973	-68%	-$769K	﹤0.01%	5079
2017 Q3	$1.14M	Buy	+67,618	New	+$1.11M	﹤0.01%	4337

Morgan Stanley's CMTA Position: Q2 2019 in Review

Morgan Stanley sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q2 2019, closing a stake of 24,513 shares — an estimated $639K sold.

Morgan Stanley first reported a position in CMTA in Q3 2017 and held it in 7 quarters. The position peaked at $1.14M in Q3 2017. 0 funds tracked by Wall St. Rank hold CMTA as of Q2 2019.

Morgan Stanley reported no remaining Clementia Pharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
Morgan Stanley sold 24,513 Clementia Pharmaceuticals Inc. shares in Q2 2019, an estimated $639K.
Morgan Stanley first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 7 quarters.
Morgan Stanley's Clementia Pharmaceuticals Inc. position peaked at $1.14M in Q3 2017.
0 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q2 2019.

Based on Morgan Stanley's 13F filing for Q2 2019, filed 14 Aug 2019.